Insys Buvaya Faces Negative FDA Clinical Review Ahead Of Advisory Committee; Abuse Risk May Be Even Bigger Obstacle

Prevision Policy Clips | CMS to Part D Plans: Don’t Gag

FDA Opioid Policy Bills Head To House Floor – After Some Debate; Part B Changes For Non-Opioid Analgesics Clear Committee But Still Controversial

FDA “Name And Shame” List: Products Without A REMS May Have Most Vulnerability

Prevision Policy Clips | Lucemyra (Lofexidine) FDA Approval For Short-Term Opioid Withdrawal Symptom Treatment

CMS Opens Nation Coverage Analysis for CAR-Ts, MEDCAC Scheduled For August

Medicaid Drug Formulary Demo In Discussion Stages, HHS Secretary Azar Says

Prevision Policy Clips | CMS Medicare Drug Spend Dashboards Released May 15

CMS Medicare/Medicaid Dashboard Updated With Focus On Price Increases To Federal Programs

AstraZeneca Using Patient Input To Design Better, Less-Expensive Clinical Trials; Fasenra and Anifrolumab Are Case Studies

Senate Health Committee Plans Drug Pricing Hearing Following President’s Plan; 340B Oversight Continues With Third Hearing To Come

Prevision Policy Clips | HHS Drug Pricing Plan, Request For Information Appear In Federal Register

Achondroplasia Clinical Trial Review By FDA Panel Reaches Consensus on Randomized Trials, Annual Growth Velocity Endpoint

Drug Pricing Plan First Steps: Policy Changes Start “This Week” – But With Small Steps

Tougher Talk On Drug Prices From HHS Secretary Azar: Beware The Bully Pulpit

Prevision Policy Clips | Pediatric Cancer Study Plan Workshop Focus of Oncologic Drugs Advisory Committee Meeting

Drug Pricing’s Made-For-TV Moment: Key Takeaways From The Rose Garden Event

Part B Reforms In Drug Pricing Plan May Have Biggest Impact: Reviving “CAP” Among “Immediate” Actions; “Site Neutrality,” Part D Merger Are Longer-Term Ideas

Akcea Triglyceride-Lowering Drug Volanesorsen Squeaks By Advisory Committee; FDA In A Bind Given Thrombocytopenia Risk

Prevision Policy Clips | The Reality Show President Makes Drug Pricing “Must See TV”

HHS’ Azar Delivers Drug Pricing Preview At Senate Appropriations Hearing: “All Players Will Be Impacted”

Tissue Agnostic Cancer Approvals Complicate Orphan Drug Designations; FDA Plans Guidance Soon – With Eye Toward Non-Cancer Implications

Prevision Policy Clips | OTC Monograph Reform/User Fee Bill Moves To House Floor

Wholesalers Offer Opioid Mea Culpas: House Hearing With CEOs Stays Mostly Friendly – And May Offer Lessons For Manufacturers; Focus Shifts Back To DEA

Insulin Price Increases Spotlighted By Senate Aging Committee Ahead of Trump Drug Pricing Plan